Andrew Lo Biography and Net Worth

Director of AbCellera Biologics

Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He is a cofounder and director of BridgeBio Pharma, a director of Atomwise and Roivant Sciences, a cofounder and chairman of QLS Advisors, and a member of the advisory boards of NCATS and the American Cancer Society’s BrightEdge Impact Fund. Dr. Lo is currently the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT's Computer Science and Artificial Intelligence Laboratory. Dr. Lo was named one of TIME’s “100 most influential people in the world.”

What is Andrew Lo's net worth?: The estimated net worth of Andrew Lo is at least $110.07 million as of June 4th, 2019. Dr. Lo owns 40,765,599 shares of AbCellera Biologics stock worth more than $110,067,117 as of November 10th. This net worth estimate does not reflect any other assets that Dr. Lo may own. Learn More about Andrew Lo's net worth.
How do I contact Andrew Lo?: The corporate mailing address for Dr. Lo and other AbCellera Biologics executives is , , . AbCellera Biologics can also be reached via phone at 604-559-9005 and via email at [email protected]. Learn More on Andrew Lo's contact information.
Has Andrew Lo been buying or selling shares of AbCellera Biologics?: Andrew Lo has not been actively trading shares of AbCellera Biologics during the last quarter. Most recently, on Friday, December 3rd, Andrew Lo bought 86,938 shares of AbCellera Biologics stock. The stock was acquired at an average cost of $14.02 per share, with a total value of $1,218,870.76. Learn More on Andrew Lo's trading history.
Who are AbCellera Biologics' active insiders?: AbCellera Biologics' insider roster includes Andrew Booth (CFO), John Hamer (Director), Carl Hansen (CEO), Michael Hayden (Director), Veronique Lecault (COO), Andrew Lo (Director), and John Montalbano (Director). Learn More on AbCellera Biologics' active insiders.

Andrew Lo Insider Trading History at AbCellera Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/3/2021	Buy	86,938	$14.02	$1,218,870.76

Andrew Lo Buying and Selling Activity at AbCellera Biologics

AbCellera Biologics Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Today's Range

Now: $2.70

$2.62

$2.75

50 Day Range

MA: $2.64

$2.39

$2.89

2 Week Range

Now: $2.70

$2.34

$6.05

Volume

2,167,497 shs

Average Volume

2,022,780 shs

Market Capitalization

$797.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.